In order to understand the opportunity in the therapeutic world...

In order to understand the opportunity in the therapeutic world of antisense oligonucleotides, its helpful to tune into Ionis Pharmaceuticals. Its all about specificity, broad applicability, rational design and efficiency. Its the power of precision medicine. One outstanding ASO drug success is Spinraza: developed by Ionis in collaboration with Biogen for the treatment of spinal muscular atrophy. Another is Eteplirsen. The story of the development of Eteplirsen is well known. It also brings the story home to Perth.

This is the opportunity for Phylogica. The Centre for Molecular Medicine and Innovative Therapeutics are world leaders in the development of ASOs. At the same time, Phylogica is on a path to demonstrate that it has the leading global technology for the delivery of antisense drugs.

Everything is hidden in plain sight which makes it impossible to make any definitive statements. One day there will be a formal announcement possibly following the in vivo results with second generation CPPs. In the meantime, we can see where it is going. The directors of Ionis saw their future as did Sarepta. It seems a long way to go from micro cap to a billion dollar valuation but in reality it comes down to a couple of years from the first clinical breakthrough.